Daniel J. O'Connor - 01 Jun 2022 Form 4 Insider Report for SEELOS THERAPEUTICS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Jun 2022
Net transaction value: +$9,789
SEC form: 4
Accepted by SEC: 02 Jun 2022, 16:29:45 UTC
Prior SEC filing: 10 Mar 2022
Next SEC filing: 14 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Golembiewski, as attorney-in-fact for Daniel J. O'Connor

Key filing fact

Daniel J. O'Connor filed Form 4 for SEELOS THERAPEUTICS, INC. on 02 Jun 2022.

Key facts

This page summarizes Daniel J. O'Connor's Form 4 filing for SEELOS THERAPEUTICS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2022, 16:29.

Change

Previous filing in this sequence was filed on 10 Mar 2022.
Current net transaction value: +$9,789.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SEEL transaction

Common Stock

Purchase

Transaction value: $9,789
Shares: +16,000
Change %
Price: $0.6118
Shares after: 16,000
Date: 01 Jun 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $0.6054 per share to $0.6127 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.

SEC remarks

Exhibit 24 - Power of Attorney